<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620408</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-110</org_study_id>
    <nct_id>NCT04620408</nct_id>
  </id_info>
  <brief_title>Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers</brief_title>
  <official_title>Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers (Single Center, Randomized, Open, Double Crossover)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effect of food on the pharmacokinetics&#xD;
      of SHR4640 tablets in healthy volunteers. The secondary objective of the study is to observe&#xD;
      the safety of SHR4640 tablets in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were&#xD;
      respectively given SHR4640 tablet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1 to Day11</time_frame>
    <description>Maximum observed concentration,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day1 to Day11</time_frame>
    <description>Area under the curve from the time of dosing Dosing time to the last measurable (positive) concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Day1 to Day11</time_frame>
    <description>Area under the curve from time 0 to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sUA</measure>
    <time_frame>Day1 to Day11</time_frame>
    <description>concentration of serum urine acid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in group A did not have breakfast at D1, then were given an SHR4640 tablet. The subjects in group A had a high-fat breakfast on D8. After eating 30min, the subjects in group A were given SHR4640 tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B had high-fat breakfast on D1, no breakfast on D8, and the rest was the same as group A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640</intervention_name>
    <description>Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign the informed consent form before the start of the activities related&#xD;
             to this trial, and be able to understand the procedures and methods of this trial, and&#xD;
             be willing to strictly abide by the clinical trial plan to complete this trial.&#xD;
&#xD;
          2. Aged between 18 and 45 years old (including both ends, whichever is the time of&#xD;
             signing the informed consent form), male.&#xD;
&#xD;
          3. Body weight ≥ 50 kg, and body mass index (BMI): 19-26 kg/m2 (both ends included).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a fertility plan within 3 months after screening to the last medication, or&#xD;
             refuse to use medically approved contraceptive methods.&#xD;
&#xD;
          2. Drug abusers or drug urine screening positive.&#xD;
&#xD;
          3. Smokers (average daily smoking 5 or more).&#xD;
&#xD;
          4. Those who consumed more than 25 grams of alcohol per day during the first month were&#xD;
             screened or were positive for alcohol breath test.&#xD;
&#xD;
          5. Anyone who had eaten grapefruit or fruit juice products within 2 days before&#xD;
             administration, any food or drink containing caffeine (such as coffee, tea, chocolate,&#xD;
             cola or other caffeinated carbonated drinks, etc.) and foods or drinks rich in purine&#xD;
             food or alcohol.&#xD;
&#xD;
          6. The researchers judged that the subjects had medical conditions that affected the&#xD;
             absorption, distribution, metabolism and excretion of drugs or reduced compliance.&#xD;
&#xD;
          7. Those with sUA &gt; 420 µmol / L during the screening period, or those with a previous&#xD;
             history of hyperuricemia and / or gout.&#xD;
&#xD;
          8. Those with estimated glomerular filtration rate (eGFR) &lt; 90 (mL/min/1.73 m²) during&#xD;
             the screening period.&#xD;
&#xD;
          9. Those with urolithiasis indicated or suspected by B ultrasound during the screening&#xD;
             period.&#xD;
&#xD;
         10. Those who were positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C&#xD;
             virus (HCV) antibody, human immunodeficiency virus (HIV) antibody or syphilis antibody&#xD;
             within one month or during the screening period.&#xD;
&#xD;
         11. Any clinical history of serious illness or disease or condition that the researchers&#xD;
             believe may affect the results of the trial, including, but not limited to, a history&#xD;
             of circulatory, endocrine, nervous, digestive, urinary or hematological, immune,&#xD;
             mental and metabolic diseases.&#xD;
&#xD;
         12. People with allergies, including those who are explicitly allergic to research drugs&#xD;
             or any ingredient in research drugs, are allergic to any food ingredient or have&#xD;
             special requirements for diet, and are unable to follow a uniform diet.&#xD;
&#xD;
         13. Screening those who have undergone any operation within the first 3 months, or who&#xD;
             have not recovered after the operation, or who may have a plan for operation or&#xD;
             hospitalization during the trial.&#xD;
&#xD;
         14. Those who donated blood (or lost blood) within the first 3 months and donated blood&#xD;
             (or lost blood) more than 400 mL, or received blood transfusion.&#xD;
&#xD;
         15. Screen people who have participated in clinical trials of any drug or medical device&#xD;
             within the previous 3 months.&#xD;
&#xD;
         16. Take any prescription drug, over-the-counter medicine, Chinese herbal medicine or&#xD;
             dietary supplement within 2 weeks before the screening period.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beibei Liang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of the Chinese people's Liberation Army</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheng Zhong, Master</last_name>
    <phone>+86 13564101315</phone>
    <email>zhongsheng@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxiong Gao, PhD</last_name>
    <phone>+86 19821262236</phone>
    <email>gaoyuxiong@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

